ANTIBIOTICS

CHOICES FOR COMMON INFECTIONS

2017 EDITION bpac nz

better medicine
For updates to this guide see www.bpac.org.nz/antibiotics
Antibiotic choices for common infections
The following information is a consensus guide. It is intended to aid selection of an
appropriate antibiotic for typical patients with infections commonly seen in general
practice. Individual patient circumstances and local resistance patterns may alter
treatment choices.
Antibiotic use in New Zealand is higher per head of population than in many similar
developed countries. Increased antibiotic use leads to the development of resistance
by eliminating antibiotic-susceptible bacteria and leaving antibiotic-resistant bacteria
to multiply. Antimicrobial stewardship aims to limit the use of antibiotics to situations
where they deliver the greatest clinical benefit. Along with infection control, this is the key
strategy to counter the emerging threat of antimicrobial resistance.

General principles of antimicrobial stewardship:

1. In most cases, only prescribe antibiotics for bacterial infections if:
■ Symptoms are significant or severe
■ There is a high risk of complications
■ The infection is not resolving or is unlikely to resolve

2. Select the first-line indicated antibiotic at the recommended dose and duration
3. Reserve broad spectrum antibiotics for indicated conditions only
4. Prioritise consideration of antibiotic resistance over palatability issues and
convenience of dosing regimens when deciding which antibiotic to prescribe
5. Educate patients about responsible use of antibiotics, including when an antibiotic is
not indicated

Information on national antimicrobial resistance patterns is available from the

Institute of Environmental Science and Research Ltd (ESR), Public Health Surveillance:
www.surv.esr.cri.nz

Regional resistance patterns may vary; check with your local laboratory.

  To check the subsidy status of a medicine, refer to the New Zealand Formulary:
www.nzformulary.org or the Pharmaceutical Schedule:
www.pharmac.govt.nz/tools-resources/pharmaceutical-schedule

For an electronic version of this guide see:

www.bpac.org.nz/antibiotics

The information in this guide is correct as at the time of publication: July, 2017.
 Respiratory
Respiratory
COPD – acute exacerbations
Management Antibiotic treatment is usually only necessary for patients with
moderate to severe signs and symptoms of infection.
Approximately half of COPD exacerbations are triggered by viruses
rather than bacteria. Antibiotic treatment is more likely to be
helpful in patients with clinical signs of chest infection (e.g. purulent
sputum and increased shortness of breath and/or increased volume
of sputum) and those with more severe airflow obstruction at
baseline.

Common pathogens Respiratory viruses, Streptococcus pneumoniae, Haemophilus

influenzae, Moraxella catarrhalis

Antibiotic treatment Acute exacerbation of COPD with moderate to severe signs of

infection

First choice Amoxicillin

Adult: 500 mg, three times daily, for five days*

Alternatives Doxycycline
Adult: 200 mg, on day one (loading dose), followed by 100 mg,
once daily, on days two to five*

* Longer courses may not provide additional clinical benefit

Pertussis (whooping cough)

Management Antibiotic treatment is recommended to reduce transmission, if
initiated within three weeks of the onset of the cough; after this time
most people are no longer infectious.
Antibiotic treatment is also recommended if the duration of the
cough is unknown, and for pregnant women with pertussis.
Prophylactic antibiotics are recommended for high risk contacts:
children aged less than one year and their caregivers, pregnant
women and people at risk of complications, e.g. severe asthma,
immunocompromised.
Antibiotic treatment is unlikely to alter the clinical course of the illness,
unless given within the first few days of contracting the infection.
However, as initial symptoms are often indistinguishable from a
minor respiratory infection, antibiotics are not usually considered
early on unless there is reason to suspect pertussis infection, e.g.
family contacts.
continued over page

1
Respiratory

Management Patients should be advised to avoid contact with others, especially

continued infants and children, until at least five days of antibiotic treatment
has been taken. Children with pertussis can deteriorate rapidly and
may require hospitalisation.
Pertussis is a Notifiable Disease. Suspected cases must be notified
to the Medical Officer of Health. Check with the local Medical
Officer of Health as to whether laboratory testing is appropriate.

Common pathogens Bordetella pertussis

Antibiotic treatment Pertussis symptoms < 3 weeks or high risk contact

First choice Azithromycin*

Child < 45 kg: 10 mg/kg/dose, once daily, on day one, followed by 5
mg/kg/dose, once daily, on days two to five
Adult and child > 45 kg: 500 mg on day one, followed by 250 mg,
once daily, on days two to five
* Macrolide antibiotics are associated with a risk of development of
hypertrophic pyloric stenosis in infants aged under two weeks. However,
the benefits of treating pertussis outweigh this risk; azithromycin is the
preferred macrolide during pregnancy, lactation and in infants aged < 1
month.

Alternatives Erythromycin*
Child: 10 mg/kg/dose, four times daily, for 14 days
Adult: 400 mg, four times daily, for 14 days
* See note above re. macrolides

Trimethoprim + sulfamethoxazole† (for adults and children aged

> 6 weeks allergic to macrolides)
Child: 24mg/kg/dose, twice daily, for 14 days
Adult: 960 mg (two tablets), twice daily, for 14 days
† Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL or
co-trimoxazole tablets 80+400 mg; now expressed as the total dose of
trimethoprim + sulfamethoxazole (ratio 1:5) – 240 mg/5 mL oral liquid or
480 mg tablets. N.B. avoid in infants aged under six weeks, due to the risk
of hyperbilirubinaemia.

2
 Respiratory
Pneumonia – adult
Management Antibiotic treatment is appropriate for all adults with suspected
pneumonia.
Adults with pneumonia may present with symptoms and signs
specific to the chest, or less specific respiratory and systemic
symptoms, e.g. confusion (particularly in elderly people). Consider
referral to hospital for patients with one or more of the following
features: co-morbidities, altered mental state, respiratory rate >30/
min, pulse rate >125/min, O2 saturation ≤92%, BP systolic <90
mm Hg or diastolic <60 mm Hg, age > 65 years, lack of reliable
observation at home.
Chest x-ray is not routinely recommended in a community setting.
It may be appropriate when the diagnosis is unclear, there is
dullness to percussion or other signs of an effusion or collapse, or
when the likelihood of malignancy is increased, such as in a smoker
aged over 50 years.

Common pathogens Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma

pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila,
Staphylococcus aureus, respiratory viruses
N.B. Patients can generally be adequately treated with an antibiotic
that covers S. pneumoniae.

Antibiotic treatment Suspected or confirmed pneumonia

First choice Amoxicillin

Adult: 500 mg – 1 g, three times daily, for five to seven days
If atypical organisms are suspected, e.g. M. pneumoniae, C.
pneumoniae or L. pneumophila, or if the patient has not improved
after 48 hours, add either:
Roxithromycin 300 mg, once daily, for seven days; or
Doxycycline 200 mg, twice daily, on day one, followed by 100
mg, twice daily, from days two to seven

Alternatives Monotherapy with roxithromycin or doxycycline is acceptable for

people with a history of penicillin allergy.
N.B. Ciprofloxacin should not be used as it does not reliably treat
infections due to S. pneumoniae.

3
Respiratory

Pneumonia – child
Management Antibiotic treatment is appropriate for all children with suspected
pneumonia.
Children with pneumonia may present with a range of respiratory
symptoms and signs; fever, tachycardia and increased respiratory
effort are more common, auscultatory signs are less common.
Consider referral to hospital for a child with any of the following
features: age < 6 months, drinking less than half their normal
amount, oxygen saturation ≤ 92% on air, increased respiratory
effort, temperature < 35°C or > 40°C, decreased breath sounds or
dullness to percussion, lack of reliable observation at home.
In addition, if there is no response to treatment in 24 – 48 hours,
review diagnosis and consider referral to hospital.
Chest x-ray is not routinely recommended in a community setting.
It may be appropriate when the diagnosis is unclear, there is
dullness to percussion or other signs of an effusion or collapse or
the history is suggestive of foreign body aspiration.

Common pathogens Streptococcus pneumoniae, Haemophilus influenzae, Mycoplasma

pneumoniae, Staphylococcus aureus, respiratory viruses

Antibiotic treatment Suspected or confirmed pneumonia

First choice Amoxicillin

Child: 25 – 30 mg/kg/dose, three times daily, for five to seven days
(maximum 500 mg/dose age three months to five years, 1000 mg/
dose age > five years)

Alternatives Erythromycin
Child: 10 – 12.5 mg/kg/dose, four times daily, for seven days
N.B. Can be first-line in school-aged children where the likelihood of
atypical pathogens is higher.
Roxithromycin*
Child < 40 kg: 2.5 – 4 mg/kg/dose (maximum 150 mg), twice daily,
for seven to ten days
Child > 40 kg: 150 mg, twice daily, for seven to ten days
* Roxithromycin is now also available in a 50 mg dispersable tablet for
children < 12 years.

4
Ear, nose and throat
Otitis externa – acute
Management Antibiotic treatment (topical) should only be considered if
secondary infection is present.
First-line management is gentle cleansing of the external ear canal,
e.g. with suction, a wick or probe. If signs of infection persist after

E.N.T.
thorough cleansing, a solution containing an anti-infective and a
corticosteroid may be considered. Underlying chronic otitis media
should be excluded before treatment. Most topical antibacterials
are contraindicated in the presence of a perforated drum or
grommets; they may, however, be used with caution if cleansing of
the ear canal alone has been unsuccessful in resolving symptoms.
Patients with acute infection should be advised to avoid immersing
their ears while swimming or to wear a protective cap.
N.B. People with diabetes or who are immunocompromised are at
risk of necrotizing or malignant otitis externa.

Common pathogens Staphylococcus aureus, Streptococcus pyogenes, Pseudomonas

aeruginosa, polymicrobial infections

Antibiotic treatment Otitis externa with secondary infection

First choice Flumethasone + clioquinol (Locorten Vioform)

Adult and child > 2 years: 2 to 3 drops, twice daily, for seven days
OR
Dexamethasone + framycetin + gramicidin (Sofradex)
Adult and child: 2 to 3 drops, three to four times daily, for seven
days
N.B. Avoid using drops for longer than one week as this may result in fungal
infection which can be difficult to treat

Alternatives Acetic acid 2% (Vosol) may be sufficient in mild cases.

Triamcinolone + neomycin + gramicidin + nystatin (Kenacomb) if
fungal infection is suspected
Ciprofloxacin + hydrocortisone (Ciproxin HC) if Pseudomonas
suspected.
Framycetin (Soframycin) if a steroid is not required as part of the
preparation.

5
 Otitis media – acute
Management Antibiotic treatment is usually unnecessary as most infections are
self-limiting.
Consider antibiotics for children at high risk, e.g. with systemic
symptoms, aged < 6 months, aged < 2 years with severe or bilateral
infection, with perforation and/or otorrhoea or if there has been no
improvement within 48 hours. Also consider antibiotics in children
E.N.T.

with recurrent infections, i.e. three or more episodes of otitis media

within six months or four or more within 12 months.
Otherwise treat symptomatically, e.g. paracetamol, and arrange
follow up or give a “back pocket” prescription to be dispensed if no
improvement in next 24 – 48 hours.
Otitis media with effusion – antibiotics provide little or no long-
term benefit in children without acute symptoms; watchful waiting
is recommended. Consider referral to otorhinolaryngology (ENT)
if recurrent acute otitis media or persistent bilateral middle ear
effusions for more than three months.

Common pathogens Respiratory viruses, Streptococcus pneumoniae, Haemophilus

influenzae, Moraxella catarrhalis

Antibiotic treatment Otitis media in child with risk factors or recurrent infection

First choice Amoxicillin

Child: 15 mg/kg/dose, three times daily, for five days.
N.B. Treat for seven to ten days if aged < 2 years, underlying
medical condition, bilateral otitis media or perforated ear drum
For severe or recurrent infection use 30 mg/kg/dose, three times
daily, for five to seven days (maximum 500 mg/dose age three
months to five years, 1000 mg/dose age > 5 years).

Alternatives Trimethoprim + sulfamethoxazole*

Child > 6 weeks: 24 mg/kg/dose, twice daily, for five to seven days
* Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5mL; now
expressed as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5)
– 240 mg/5 mL oral liquid. N.B. avoid in infants aged under six weeks, due
to the risk of hyperbilirubinaemia.

6
Pharyngitis
Management Antibiotic treatment is recommended for people at high risk of
rheumatic fever.
Pharyngitis is of viral origin in approximately half of cases, and
usually self-limiting, therefore antibiotic treatment is unnecessary in
most cases. The exception to this is treating Group A Streptococcus
pyogenes pharyngitis in high risk people to prevent rheumatic fever.

E.N.T.
Those at high risk for rheumatic fever are defined as individuals
who have a personal, family or household history of rheumatic
fever, or who have two or more of the following criteria: Māori or
Pacific ethnicity, age 3 – 35 years or living in crowded circumstances
or in lower socioeconomic areas.
Refer to the New Zealand Heart Foundation Guidelines for further
guidance.

Common pathogens Respiratory viruses, Streptococcus pyogenes

Antibiotic treatment Group A streptococcal pharyngitis in patients at high risk of

rheumatic fever

First choice Phenoxymethylpenicillin (Penicillin V)

Child < 20 kg: 250 mg, two or three times daily, for ten days
Child ≥ 20 kg and Adults: 500 mg, two or three times daily, for ten
days
OR
Amoxicillin
Child < 30 kg: 750 mg or 50 mg/kg (maximum 1000 mg/day), once
daily, for ten days OR 25 mg/kg/dose (maximum 1000 mg/day),
twice daily, for ten days
Child ≥ 30 kg and Adults: 1000 mg, once daily, for ten days OR 25
mg/kg/dose (maximum 1000 mg/day), twice daily, for ten days
OR
IM benzathine penicillin (stat)
Child < 30 kg: 450 mg (600 000 U)
Child ≥ 30 kg and Adults: 900 mg (1 200 000 U)

Alternatives Erythromycin
Child: 40 mg/kg/day divided in 2–3 doses for ten days (usual
maximum 1.6 g/day)
Adult: 400 mg, twice daily, for ten days
Roxithromycin*
Child < 40 kg: 2.5 mg/kg/dose, twice daily, for ten days
Child > 40 kg: 150 mg, twice daily, for ten days
Adult: 300 mg, once daily or 150 mg, twice daily, for ten days
* Roxithromycin is now also available in a 50 mg dispersable tablet for
children < 12 years.

7
 Sinusitis – acute
Management Antibiotic treatment is not required in the majority of cases.
More than 90% of patients with sinusitis will not have a bacterial
infection. Even in the small minority that do, symptoms are self-
limiting and antibiotics only offer a marginal benefit.
Antibiotics may be considered for patients with symptoms that
E.N.T.

persist for more than ten days, onset of severe symptoms or fever
(>39°C) and purulent nasal discharge or facial pain lasting for at
least three consecutive days, or onset of worsening symptoms after
initial improvement.

Common pathogens Respiratory viruses, Streptococcus pneumoniae, Haemophilus

influenzae, Moraxella catarrhalis, anaerobic bacteria

Antibiotic treatment Persistent or severe sinusitis

First choice Amoxicillin

Child: 25 – 30mg/kg/dose, three times daily, for seven days
(maximum 500 mg/dose age three months to five years, 1000 mg/
dose age > 5 years)
Adult: 500 – 1000 mg, three times daily for seven days

Alternatives Doxycycline
Adult and child > 12 years: 200 mg on day one, followed by 100
mg, once daily, on days two to seven
Amoxicillin clavulanate* (if symptoms persist despite a treatment
course of amoxicillin)
Child: 15 – 30 mg/kg/dose, three times daily, for seven days
(maximum 500 mg/dose)
Adult: 625 mg, three times daily, for seven days
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

8
Eyes
Conjunctivitis
Management Antibiotic treatment is only required for patients with severe
symptoms indicative of bacterial infection.
Conjunctivitis can be viral, bacterial or allergic. Bacterial
conjunctivitis is usually associated with purulent discharge.
Symptoms are self-limiting and the majority of people improve
without treatment, in two to five days. Conjunctivitis due
to adenovirus and enterovirus is also self limiting. Patients
with suspected HSV conjunctivitis require evaluation by an
ophthalmologist.
In newborn infants, consider Chlamydia trachomatis or Neisseria
gonorrhoeae, in which case, do not use topical treatment.
Collect appropriate eye swabs and refer to a paediatrician or

Eyes
ophthalmologist.
Patients with conjunctivitis can be advised to clean away
secretions from the eyelids and eyelashes using cotton wool
soaked in water. Advise hand washing after touching the eyes and
avoid sharing pillows, facecloths and towels. Do not wear contact
lenses. Artificial tear drops can be used to relieve discomfort.

Common pathogens Viruses including HSV, Streptococcus pneumoniae, Haemophilus

influenzae, Staphylococcus aureus. Less commonly: Chlamydia
trachomatis or Neisseria gonorrhoeae

Antibiotic treatment Severe bacterial conjunctivitis

First choice Chloramphenicol 0.5% eye drops

Adult and child > 2 years: 1 – 2 drops, every 2 – 6 hours* until
48 hours after symptoms have cleared (or five days, whichever is
shorter). Chloramphenicol 1% eye ointment may also be used at
night in patients with severe infection or as an alternative to eye
drops.
* Frequency of administration can be reduced after two to three days

Alternatives Framycetin eye/ear drops (Soframycin)

Adult and child: 2 drops every 1 – 2 hours reducing to 2 – 3 drops,
three times daily, until 48 hours after symptoms have cleared.
Fusidic acid eye gel 1%
Adult and child: 1 drop, twice daily until 48 hours after symptoms
have cleared.

Periorbital cellulitis – see Cellulitus (Page 13)

9
 CNS
Meningitis and meningococcal septicaemia
Management Antibiotic treatment should be given to all patients with suspected
meningitis or meningococcal septicaemia, while awaiting transport
to hospital (if this does not delay transfer).
Immediately refer all people with suspected meningitis or
meningococcal septicaemia to hospital. Record observations,
including neurological assessment, at least every 15 minutes
while awaiting transfer. The first stage of meningococcal disease
is associated with non-specific influenza-like symptoms and signs.
Specific signs and symptoms of bacterial meningitis include:
photophobia, severe headache, neck stiffness and focal neurologic
deficit. Meningococcal septicaemia may be indicated by features
such as non-blanching rash, unusual or mottled skin colour and
rapidly deteriorating condition. Most patients will not display
specific signs within the first four to six hours of illness (up to eight
hours for adolescents) and infants may not display typical signs at
all.
Meningococcal disease is notifiable on suspicion.

Common pathogens Neisseria meningitidis, Streptococcus pneumoniae. Viral:

enteroviruses, Herpes simplex virus, Varicella zoster virus and other
CNS

viruses.
Rare: Listeria monocytogenes, Haemophilus influenzae
Infants: Group B Streptococcus, L. monocytogenes, E.coli

Antibiotic treatment Suspected meningitis or meningococcal septicaemia

First choice Benzylpenicillin (penicillin G)

Child < one year: 300 mg IV or IM
Child 1 – 9 years: 600 mg IV or IM
Child > 10 years and Adult: 1.2 g IV or IM

Alternatives Ceftriaxone
Child and Adult: 50 – 100 mg/kg (up to 2 g) IV or IM
N.B. Almost any parenterally administered antibiotic in an
appropriate dose will inhibit the growth of meningococci, so if
benzylpenicillin or ceftriaxone are not available, give any other
penicillin or cephalosporin antibiotic.

10
Skin
Bites – human and animal
Management Antibiotic treatment is recommended for all patients with infected
bites or as prophylactic treatment, depending on the nature of the
bite.
Prophylactic antibiotic treatment is recommended for human,
dog or cat bites, severe or deep bites, bites on the hand, foot, face,
tendon or ligament, in immunocompromised people and people
presenting with an untreated bite, more than eight hours later.
Clean and debride the wound thoroughly and assess the need for
tetanus immunisation.
Refer to hospital if there is bone or joint involvement.

Common pathogens Polymicrobial infection, Pasteurella multocida, Capnocytophaga

canimorsus (cat and dog bites), Eikenella corrodens (fist injury),
Staphylococcus aureus, streptococci and anaerobes

Antibiotic treatment Infected bite or prophylaxis if risk factors

First choice Amoxicillin clavulanate*

Child: 15 – 30 mg/kg/dose (maximum 500 mg/dose), three times
daily, for seven days
Adult: 625 mg, three times daily, for seven days
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

Alternatives Child > 12 years and Adult: Metronidazole 400 mg, three times
daily, plus doxycycline 200 mg on day one, followed by 100 mg,
once daily, on days two to seven.
Child < 12 years: Metronidazole 7.5 mg/kg/dose (maximum 400

Skin
mg), three times daily plus trimethoprim + sulphamethoxazole*
24 mg/kg/dose, twice daily, for seven days (maximum 20 mL/dose).
* Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL; now
expressed as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5)
– 240 mg/5 mL oral liquid. N.B. avoid in infants aged under six weeks, due
to the risk of hyperbilirubinaemia.

11
 Boils (furuncles)
Management Antibiotic treatment is not usually required. Most lesions should be
treated with incision and drainage alone. A topical antiseptic may
be useful.
Antibiotics may be considered if there is fever, spreading cellulitis
or co-morbidity, e.g. diabetes, or if the lesion is in a site associated
with complications, e.g. the face.

Common pathogens Staphylococcus aureus

Consider MRSA if there is a lack of response to flucloxacillin, another
penicillin or cephalosporin.

Antibiotic treatment Boils (with complications)

First choice Flucloxacillin

Child: 12.5 – 25 mg/kg/dose, three to four times daily, for five days
Adult: 500 mg, four times daily, for five days

Alternatives Erythromycin (if allergy to flucloxacillin or MRSA present*)

Child aged < 12 years: 20 mg/kg/dose, twice daily, or 10 mg/kg/
dose, four times daily, for five days (maximum 1 g/day)
Adult: 800 mg, twice daily, or 400 mg, four times daily, for five days
Trimethoprim + sulfamethoxazole† (if allergy to flucloxacillin or
MRSA present*)
Child > 6 weeks: 24 mg/kg/dose, twice daily, for five to seven days
(maximum 960 mg/dose)
Child >12 years and Adult: 960 mg (two tablets), twice daily, for five
to seven days
Cefalexin (if flucloxacillin not tolerated)
Child: 12.5 – 25 mg/kg/dose, twice daily, for five days
Adult: 500 mg, four times daily, for five days
Skin

* Based on MRSA susceptibilities

† Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL or
co-trimoxazole tablets 80 + 400 mg; now expressed as the total dose of
trimethoprim + sulfamethoxazole (ratio 1:5) – 240 mg/5 mL oral liquid or
480 mg tablets. N.B. avoid in infants aged under six weeks, due to the risk
of hyperbilirubinaemia.

12
Cellulitis
Management Antibiotic treatment is required for all patients with cellulitis. Oral
antibiotic treatment is appropriate for those with mild to moderate
cellulitis; intravenous treatment is usually required for patients with
severe cellulitis or those not responding to oral treatment.
Keep affected area elevated (if applicable) for comfort and to relieve
oedema. Assess response to treatment in two days. Discuss referral
to hospital for consideration of IV antibiotics if cellulitis is extensive,
not responding to oral antibiotics, systemic symptoms are present
(e.g. fever, nausea, vomiting) and in young infants.
For periorbital or facial cellulitis, in all but very mild cases refer to
hospital for consideration of IV antibiotics.

Common pathogens Streptococcus pyogenes, Staphylococcus aureus, Group C or Group G

streptococci

Antibiotic treatment Mild to moderate cellulitis

First choice Flucloxacillin

Child: 12.5 – 25 mg/kg/dose, four times daily, for five days
Adult: 500 mg, four times daily, for five days

Alternatives Erythromycin (if allergy to flucloxacillin or MRSA present*)

Child < 12 years: 20 mg/kg/dose, twice daily, or 10 mg/kg/dose,
four times daily, for five days (maximum 1 g/day)
Adult: 800 mg, twice daily, or 400 mg, four times daily, for five days.
Trimethoprim + sulfamethoxazole† (if allergy to flucloxacillin or
MRSA present*)
Child > 6 weeks: 24 mg/kg/dose, twice daily, for five to seven days
(maximum 960 mg/dose)
Child >12 years and Adult: 960 mg (two tablets), twice daily, for five

Skin
to seven days
Cefalexin (if flucloxacillin not tolerated)
Child: 12.5 mg/kg/dose, four times daily, for five days (maximum
500 mg/dose)
Adult: 500 mg, four times daily, for five days
* Based on MRSA susceptibilities
† Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL or
co-trimoxazole tablets 80 + 400 mg; now expressed as the total dose of
trimethoprim + sulfamethoxazole (ratio 1:5) – 240 mg/5 mL oral liquid or
480 mg tablets. N.B. avoid in infants aged under six weeks, due to the risk
of hyperbilirubinaemia.

13
 Diabetic foot infections
Management Antibiotic treatment is required if there are signs of infection
in the wound. It is recommended to take a wound swab for
microbiological analysis.
The threshold for suspecting infection and testing a wound should
be lower in people with diabetes and other conditions where
perfusion and immune response are diminished, as classical clinical
signs of infection are not always present.
Referral for further assessment should be considered if infection
is suspected to involve the bones of the feet, if there is no sign of
healing after four weeks of treatment, or if other complications
develop.
Antibiotic treatment is not recommended for prevention of diabetic
foot infections.

Common pathogens Early infection is usually due to Staphylococcus aureus and/or

streptococci. Later infection may be polymicrobial with a mixture of
Gram-positive cocci, Gram-negative bacilli and anaerobes.

Antibiotic treatment Infected foot wound in adult with diabetes

First choice Amoxicillin clavulanate*

Adult: 625 mg, three times daily, for five to seven days
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

Alternatives Cefalexin 500 mg, four times daily, plus metronidazole 400 mg,
two to three times daily, for five to seven days
OR (for patients with penicillin hypersensitivity)
Trimethoprim + sulfamethoxazole* 960 mg (two tablets), twice
daily, plus
Skin

clindamycin† 300 mg, three times daily, for five to seven days
* Formerly referred to as co-trimoxazole tablets 80 + 400 mg; now expressed
as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5) – 480 mg
tablets.
† Requires specialist endorsement for > 4 capsules

14
Impetigo
Management Antibiotic treatment is not usually required initially; good skin
hygiene is the first-line management. There is a limited role for
topical antibiotic treatment; only for localised infection and
second-line to topical antiseptics. Oral antibiotic treatment is
recommended for more extensive, widespread infection, or if
systemic symptoms are present.
Initial management involves the simple measures of “clean, cut
(nails) and cover”. Use moist soaks to gently remove crusts from
lesions, keep affected areas covered and exclude the child from
school or preschool until 24 hours after treatment has been
initiated. Assess and treat other infected household members.
Topical treatment is only appropriate for areas of localised impetigo
(usually ≤ 3 lesions). Current expert opinion favours the use of
antiseptic cream, such as hydrogen peroxide or povidone-iodine,
as first choice topical treatment, due to high rates of fusidic acid
resistance in S. aureus in New Zealand.
Recurrent impetigo may be the result of chronic nasal carriage of S.
aureus (patient or household contact), or re-infection from fomite
colonisation, e.g. clothing, linen, and may require decolonization.

Common pathogens Streptococcus pyogenes, Staphylococcus aureus

Antibiotic treatment Impetigo (non-antibiotic + antibiotic treatment)

First choice Topical (localised area of infection):

Hydrogen peroxide 1% cream
Apply 2 – 3 times daily, for five days
OR
Povidone-iodine 10% ointment

Skin
Apply 2 – 3 times daily, for five days

Oral (extensive/multiple lesions) – treat as per cellulitis:

Flucloxacillin
Child: 12.5 – 25 mg/kg/dose, four times daily, for five days
(maximum 500 mg/dose)
Adult: 500 mg, four times daily, for five days
continued over page

15
 Alternatives Topical
Fusidic acid 2% cream or ointment
Apply twice daily, for five days
N.B. Use topical Fusidic acid as second line treatment after topical
antiseptics and only if the infection is localized.
If topical treatment fails, use oral treatment as above.

Oral
Trimethoprim + sulfamethoxazole* (if complicated infection,
MRSA present† or allergy to flucloxacillin)
Child > 6 weeks: 24 mg/kg/dose, twice daily, for five days
(maximum 20 mL/dose)
Child >12 years and Adult: 960 mg (two tablets), twice daily, for five
days
Erythromycin (if allergy to flucloxacillin or MRSA present†)
Child aged < 12 years: 20 mg/kg/dose, twice daily, or 10 mg/kg/
dose, four times daily, for five days (maximum 1.6 g/day)
Adult: 800 mg, twice daily, or 400 mg, four times daily, for five days
Cefalexin (if flucloxacillin not tolerated)
Child: 12 – 25 mg/kg/dose, twice daily, for five days
Adult: 500 mg, four times daily or 1 g, twice daily, for five days
* Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL or
co-trimoxazole tablets 80+400 mg; now expressed as the total dose of
trimethoprim + sulfamethoxazole (ratio 1:5) – 240 mg/5 mL oral liquid or
480 mg tablets. N.B. avoid in infants aged under six weeks, due to the risk
of hyperbilirubinaemia.
† Based on MRSA susceptibilities
Skin

16
Mastitis
Management Antibiotic treatment is required for severe, worsening or persistent
symptoms.
Conservative management to alleviate symptoms (e.g. gentle
massage, warm compress) and ongoing breast emptying may be all
that is required for treatment. If there is no improvement within 12
– 24 hours or symptoms are severe or worsening, antibiotics should
be started. Breast feeding (or expressing) from both breasts should
be continued; this is an important component of treatment and
poses no risk to the infant.

Common pathogens Staphylococcus aureus in lactating women, S. aureus and anaerobes

in non-lactating females, or in males

Antibiotic treatment Severe or non-resolving mastitis

First choice Flucloxacillin

Adult: 500 mg, four times daily, for 5 – 7 days

Alternatives Erythromycin
Adult: 400 mg, four times daily, for 5 – 7 days
Cephalexin
Adult: 500 mg, four times daily, for 5 – 7 days
N.B. Treat mastitis in males or non-lactating females with
amoxicillin clavulanate* 625 mg, three times daily, for seven days
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

Skin

17
 Gastrointestinal
Campylobacter enterocolitis
Management Antibiotic treatment is recommended for people with symptoms
that are severe (e.g. high fever, bloody diarrhoea) or prolonged (> 7
days).
Antibiotics may also be considered for people at high risk of
complications or those who are at higher risk of transmitting
infection to vulnerable people (although this is rare). This includes
pregnant women, people who are immunocompromised and their
carers, food handlers and childcare workers.
Most people will recover with symptomatic treatment only,
including rehydration. Antibiotics reduce the average duration
of symptoms by less than two days but eradicate stool carriage.
People can remain infectious to others for up to several weeks after
onset of symptoms. However, with or without antibiotic treatment,
spread from person to person is very rare.
Campylobacter enterocolitis is a notifiable disease.

Common pathogens Campylobacter jejuni

Antibiotic treatment Severe or prolonged campylobacter enterocolitis or high risk

First choice Erythromycin

Child: 10 mg/kg/dose, four times daily, for five days
Adult: 400 mg, four times daily, for five days

Alternatives Ciprofloxacin
Adult: 500 mg, twice daily, for five days (not recommended for
children)

Clostridium difficile colitis

Management Antibiotic treatment is recommended for adults who have tested
positive for C. difficile toxin, and have diarrhoea or other symptoms
Gastrointestinal

consistent with colitis.

C. difficile colitis occurs due to overgrowth of toxin-producing C.
difficile in the colon. A common cause is the use of broad spectrum
antibiotic treatment. Discontinuing such antibiotic treatment, if and
when possible, may lead to clinical resolution of symptoms.
Antidiarrhoeals, e.g. loperamide, should be avoided as the toxin
may be retained and worsen colitis. Consider referral to hospital
if there is evidence of worsening colitis. Relapse may occur after
treatment.

18
 In children, detection of C. difficile commonly represents
colonisation rather than pathological infection, so testing is
discouraged, and antibiotic treatment is not generally required in
the community setting.

Common pathogens Clostridium difficile

Antibiotic treatment Confirmed C. difficile (adults)

First choice Metronidazole

Adult: 400 mg, three times daily, for 10 days

Alternatives Vancomycin
If patient has not responded to two courses of metronidazole;
discuss with an infectious diseases physician or clinical
microbiologist. Oral vancomycin (using the injection product) may
be required.

Giardiasis
Management Antibiotic treatment is recommended for people who have tested
positive for giardia, and for symptomatic contacts.
Secondary lactose intolerance often occurs after giardiasis; patients
with ongoing symptoms after treatment can consider temporarily
avoiding lactose-containing foods (e.g. for one month).
People can remain infectious to others for up to several months
after onset of symptoms.
Giardiasis is a notifiable disease.

Common pathogens Giardia lamblia

Antibiotic treatment Confirmed giardiasis or symptomatic contact

First choice Ornidazole

Child < 35 kg: 125 mg/3 kg/dose,* once daily, for one to two days
Adult and child > 35 kg: 1.5 g, once daily, for one to two days
Gastrointestinal

* N.B. Dose is per 3 kg bodyweight; ornidazole is only available in tablet form,

tablets may be crushed, child dosing equates to one quarter of a tablet per 3
kg.
OR
Metronidazole
Child: 30 mg/kg/dose, once daily, for three days (maximum
2 g/dose)
Adult: 2 g, once daily, for three days
continued over page

19
 Alternatives For treatment failure with ornidazole:
Exclude re-infection from asymptomatic family contacts, e.g.
children
Metronidazole
Child: 10 mg/kg/dose, three times daily, for seven days, (maximum
400 mg/dose)
Adult: 400 mg, three times daily, for seven days
N.B. Nitazoxanide (hospital treatment) may be considered for
recurrent treatment failures.

Salmonella enterocolitis
Management Antibiotic treatment is usually unnecessary and may prolong
excretion. Antibiotic treatment is, however, recommended for
adults with severe disease, those who are immunocompromised
and those with prosthetic vascular grafts.
Discuss appropriate treatment for infants with a paediatrician;
those aged < 3 months will require investigation and antibiotic
management; those aged > 3 – 12 months may not, depending on
clinical state.
People typically remain infectious to others for several days to
weeks after onset of symptoms; children may remain infectious
for up to one year. However, with or without antibiotic treatment,
spread to others is very rare.

Common pathogens Salmonella enteritidis, Salmonella typhimurium

Antibiotic treatment Severe salmonella enterocolitis or risk factors

First choice Ciprofloxacin

Adult: 500 mg, twice daily, for three days

Alternatives Trimethoprim + sulfamethoxazole*

Adult: 960 mg (two tablets), twice daily, for three days
* Formerly referred to as co-trimoxazole tablets 80 + 400 mg; now expressed
Gastrointestinal

as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5) – 480 mg

tablets.

20
Genito-urinary
Bacterial vaginosis
Management Antibiotic treatment is recommended for women who are
symptomatic, pregnant or if an invasive procedure is planned, e.g.
insertion of an IUD or termination of pregnancy.
Approximately half of women found to have bacterial vaginosis are
asymptomatic; antibiotic treatment is not necessary in these cases if
there are no other risk factors. Treatment of male sexual contacts is
not usually necessary.

Common pathogens Gardnerella vaginalis, Bacteroides, Peptostreptococci, Mobilunculus

and others

Antibiotic treatment Symptomatic bacterial vaginosis or risk factors

First choice Metronidazole

Adult: 400 mg, twice daily, for seven days, or 2 g, stat, if adherence
to treatment is a concern, however, this is associated with a higher
relapse rate

Alternatives Ornidazole 500 mg, twice daily, for five days or 1.5 g, stat
Ornidazole is not recommended in women who are pregnant as no
study data is available.

Chlamydia
Management Antibiotic treatment is indicated for people with confirmed
chlamydia and their sexual partners or if there is a high suspicion of
chlamydia (symptoms and/or signs).
In suspected cases, empiric treatment should be commenced while
awaiting laboratory results.
Advise avoidance of unprotected sexual intercourse for seven days
after treatment has been initiated, and for at least seven days after
any sexual contacts have been treated, to avoid re-infection. A test
of cure should be done five weeks after initiation of treatment in
pregnant women, if a non-standard treatment has been used, e.g.
amoxicillin, or if symptoms do not resolve. Repeat STI screen in
three months.

Common pathogens Chlamydia trachomatis

continued over page

Genito-urinary

21
 Antibiotic treatment Confirmed or suspected chlamydia

First choice Azithromycin

Adult: 1 g, stat
OR
Doxycycline (if rectal infection, highly symptomatic or alternative
required)
Adult: 100 mg, twice daily, for seven days. Do not use in women
who are pregnant or breastfeeding.

Alternatives Amoxicillin (alternative for pregnant women if azithromycin

contraindicated)
500 mg, three times daily, for seven days

Epididymo-orchitis
Management Antibiotic treatment is required for all suspected cases of
epididymo-orchitis.
Epididymo-orchitis may occur due to a variety of pathogens; STI
pathogens are more likely in males aged < 35 years, with a history
of more than one sexual partner in the past 12 months, and urethral
discharge. Urinary or enteric pathogens account for other cases.
Test for chlamydia, gonorrhoea and urinary tract infection;
empirical treatment should be given while awaiting results.
If symptoms are initially severe or signs and symptoms do not
resolve (or worsen) after 24 to 48 hours, refer to hospital.
Advise avoidance of unprotected sexual intercourse for seven days
after treatment has been initiated, and for at least seven days after
any sexual contacts have been treated, to avoid re-infection.

Common pathogens Majority due to Chlamydia trachomatis or Neisseria gonorrhoeae.

Also E. coli, Bacteroides species, Gardnerella vaginalis, Mycoplasma
hominis, Ureaplasma urealyticum, Trichomonas vaginalis,
Streptococcus agalactiae and others

Antibiotic treatment Suspected epididymo-orchitis

First choice If STI pathogens suspected:

Ceftriaxone
Adult: 500 mg IM, stat (make up with 2 mL of lignocaine 1% or
according to data sheet)
AND
Doxycycline
Adult: 100 mg, twice daily, for 14 days
Genito-urinary

If UTI pathogens suspected:

Ciprofloxacin
Adult: 500 mg, twice daily, for 10 days
22
 Alternatives Amoxicillin clavulanate* 625 mg, three times daily, for 10 days (if
UTI pathogens suspected and contraindications to quinolones)
*Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

Gonorrhoea
Management Antibiotic treatment is indicated for people with confirmed
gonorrhoea and their sexual partners or if there is a high suspicion
of gonorrhoea (symptoms and/or signs).
In suspected cases, empiric treatment should be commenced while
awaiting laboratory results.
Advise avoidance of unprotected sexual intercourse for seven days
after treatment has been initiated, and for at least seven days after
any sexual contacts have been treated, to avoid re-infection. A test
of cure should be done five weeks after initiation of treatment in
pregnant women, or if a non-standard treatment has been used or
if symptoms do not resolve.
Repeat STI screen in three months. As co-infection with chlamydia
is very common, azithromycin is also routinely given.

Common pathogens Neisseria gonorrhoeae

Antibiotic treatment Confirmed or suspected gonorrhoea

First choice Ceftriaxone

Adult: 500 mg IM, stat (make up with 2 mL of 1% lignocaine or
according to data sheet)
AND
Azithromycin
Adult: 1 g, stat (including in women who are pregnant or
breastfeeding)

Alternatives If isolate is ciprofloxacin susceptible and an alternative is required:

Ciprofloxacin 500 mg, stat + azithromycin 1 g, stat
Genito-urinary

23
 Pelvic inflammatory disease
Management Antibiotic treatment is required for females who are symptomatic.
Pelvic inflammatory disease (PID) is usually caused by a STI,
particularly in women aged < 25 years, those who have had
recent change of sexual partner or those with a previous history
of gonorrhoea or chlamydia. Empiric treatment should be started
immediately on the basis of symptoms. Treatment should cover
infection with gonorrhoea, chlamydia and anaerobes.
Women with severe symptoms (e.g. fever, vomiting, acute
abdominal pain) and pregnant women require referral for specialist
assessment. Hospital admission may be required for IV antibiotics.
Advise abstinence from sexual intercourse until abdominal pain has
settled and avoidance of unprotected sexual intercourse for 14 days
after treatment has been initiated, and for at least seven days after
any sexual contacts have been treated, to avoid re-infection.

Common pathogens Chlamydia trachomatis, Neisseria gonorrhoeae and others

Antibiotic treatment Symptomatic pelvic inflammatory disease

First choice Ceftriaxone

Adult: 500 mg IM, stat (make up with 2 mL of 1% lignocaine or
according to data sheet)
AND
Doxycycline
Adult: 100 mg, twice daily, for 14 days
AND
Metronidazole
Adult: 400 mg, twice daily, for 14 days (metronidazole may be
discontinued if not tolerated)

Alternatives Ceftriaxone 500 mg IM, stat + azithromycin 1 g on day one

and day eight is an alternative if compliance is likely to be poor.
Ornidazole may be considered as an alternative, if metronidazole is
not tolerated.
Genito-urinary

24
Trichomoniasis
Management Antibiotic treatment is indicated for people with confirmed
trichomoniasis and their sexual partners or if there is a high
suspicion of trichomoniasis (symptoms and/or signs).
Empiric treatment may be commenced while awaiting laboratory
results. Due to low sensitivity, culture of urethral swabs is rarely
positive in males, even if infection is present.
Advise avoidance of unprotected sexual intercourse for seven days
after treatment has been initiated, and for at least seven days after
any sexual contacts have been treated, to avoid re-infection.
A test of cure is not usually required unless there is a risk of re-
exposure.

Common pathogens Trichomonas vaginalis

Antibiotic treatment Confirmed or suspected trichomoniasis

First choice Metronidazole

Adult: 2 g, stat

Alternatives Metronidazole 400 mg, twice daily, for seven days may be used for
those intolerant of the stat dose.
Ornidazole 1.5 g, stat or 500 mg, twice daily, for five days may be
used instead of metronidazole, but is not recommended in women
who are pregnant as no study data is available.

Urethritis – acute non-specific, male

Management Antibiotic treatment is required for males who are symptomatic.
Non-specific urethritis is a diagnosis of exclusion. A urethral swab
and first void urine sample should be taken to exclude gonorrhoea
and chlamydia (or use combination testing if available). Treat sexual
contacts if STI is present. Advise avoidance of unprotected sexual
intercourse for seven days after treatment has been initiated, and
for at least seven days after any sexual contacts have been treated,
to avoid re-infection.
Patients with symptoms persisting for more than two weeks, or
with recurrence of symptoms, should be referred to a sexual health
clinic or urologist.

Common pathogens Urethritis not attributable to Neisseria gonorrhoeae or Chlamydia

trachomatis is termed non-specific urethritis and there may be a
Genito-urinary

number of organisms responsible, e.g. Ureaplasma urealyticum,

Mycoplasma genitalium, Trichomonas vaginalis
continued over page
25
 Antibiotic treatment Symptomatic acute non-specific urethritis

First choice Azithromycin

Adult: 1 g, stat
OR
Doxycycline
Adult: 100 mg, twice daily, for seven days
If purulent discharge, treat as for gonorrhoea, i.e. ceftriaxone 500
mg IM, stat + azithromycin 1g, stat

Alternatives Nil

Urinary Tract Infection – Cystitis: adult

Management Antibiotic treatment is indicated for adults with symptoms and
signs of cystitis (lower urinary tract infection).
Urine culture is not necessary to diagnose cystitis. Urine culture is
most useful for confirming the presence of significant bacteriuria
and reporting on bacterial susceptibility to antibiotics in infections
that are considered to be complicated due to an abnormality of the
urinary tract or an underlying condition or clinical circumstance;
this includes:
■ Males
■ Pregnant women
■ People with diabetes or renal failure
■ People with a urinary catheter
■ People living in residential care facilities
■ People with persistent or recurrent cystitis (three or more
infections in one year) or atypical symptoms
N.B. Urine culture is not recommended in asymptomatic people.
However, if bacteriuria is incidentally found to be present, this only
requires antibiotic treatment in pregnant women.
Also see pyelonephritis

Common pathogens Escherichia coli, Staphylococcus saprophyticus, Proteus spp., Klebsiella

spp., Enterococcus spp.

Antibiotic treatment Symptomatic cystitis (adult)

First choice Nitrofurantoin

Adult: 50 mg, four times daily, for five days (avoid at 36+ weeks in
pregnancy, and in patients with creatinine clearance < 60 mL/min).
N.B. Treat for seven days in pregnant women and in males
OR
Trimethoprim
Genito-urinary

Adult: 300 mg, once daily, for three days (avoid during the first
trimester of pregnancy)
N.B. Treat for seven days in pregnant women and in males
26
 Alternatives Norfloxacin (only for isolates resistant to first-line choices)
Adult: 400 mg, twice daily for three days (seven days for males)
–avoid during pregnancy
N.B. If susceptibility testing indicates resistance to commonly
available antibiotics, discuss treatment with a clinical microbiologist
or infectious diseases specialist; alternative antimicrobials may be
available in some DHBs

Urinary tract infection – Cystitis: child

Management Antibiotic treatment (oral) is indicated for children aged over six
months, without known renal tract abnormalities, and who do not
have acute pyelonephritis. Refer children aged under six months,
those with severe illness, or those with recurrent infection, to
hospital for treatment.
All children with suspected urinary tract infection should have a
urine sample for culture collected (clean catch, catheter, midstream
urine) as it may be a marker for previously undetected renal
malformations, particularly in younger children. In older children it
can be a marker for bladder and/or bowel dysfunction.
  For information on collecting a urine specimen in children, see:
“Managing urinary tract infections in children”, BPJ 44 (May, 2012).

Common pathogens Escherichia coli, Proteus spp., Klebsiella spp., Enterococcus spp.

Antibiotic treatment Mild cystitis (child)

First choice Trimethoprim + sulfamethoxazole*

Child: 24 mg/kg/dose, twice daily, for three days (maximum 960
mg/dose)
* Formerly referred to as co-trimoxazole oral liquid 40+200 mg/5 mL; now
expressed as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5)
– 240 mg/5 mL oral liquid. N.B. avoid in infants aged under six weeks, due
to the risk of hyperbilirubinaemia.

Alternatives Cefalexin
Child > 1 month: 12.5 – 25 mg/kg/dose, twice daily, for three days
(maximum 1 g/dose)
Amoxicillin clavulanate*
Child: 15 mg/kg/dose, three times daily, for three days (maximum
625 mg/dose
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio
Genito-urinary

27
 Urinary Tract Infection – Pyelonephritis
Management Antibiotic treatment (oral) is required for all patients with mild
symptoms of pyelonephritis (upper urinary tract infection); patients
with more severe symptoms (e.g. vomiting, dehydration, high
fever), and all infants and children, require referral to hospital for
treatment.
Urine culture is recommended for all patients with suspected
pyelonephritis. Renal tract ultrasound may also be appropriate
depending on the clinical situation.

Common pathogens Escherichia coli, Proteus spp., Klebsiella spp., Enterococcus spp.

Antibiotic treatment Mild pyelonephritis (adult)

First choice Trimethoprim + sulfamethoxazole*

Adult: 960 mg (two tablets), twice daily, for 10 days
* Formerly referred to as co-trimoxazole tablets 80 + 400 mg; now expressed
as the total dose of trimethoprim + sulfamethoxazole (ratio 1:5) – 480 mg
tablets.

Alternatives Amoxicillin clavulanate*

Adult: 625 mg, three times daily, for 10 days
* Expressed as a combination of amoxicillin and clavulanic acid 4:1 ratio

Ciprofloxacin (only for isolates resistant to other choices)

Adult: 500 mg, twice daily, for seven days – avoid during pregnancy
N.B. Nitrofurantoin is not an appropriate choice for the treatment
of pyelonephritis as it fails to achieve tissue penetration. Oral
trimethoprim might be used in a hospital setting after IV
treatment.
Genito-urinary

28
 ACKNOWLEDGEMENT: Thank you to the Paediatric Infectious Diseases Team (Drs
Best, Lennon, Voss, Webb and Wilson), Starship Children’s Health, Dr Rosemary
Ikram, Clinical Microbiologist, Christchurch, and Associate Professor Mark
Thomas, Infectious Diseases Specialist, School of Medical Sciences, University of
Auckland, for expert review and comment on this resource.

The following references were used in the development of this guide:

1. bpacnz. Best Practice Journal. Available from: www.bpac.org.nz
2. New Zealand Formulary and New Zealand Formulary for Children. Available from: www.
nzformulary.org
3. Starship Children’s Health. Clinical guidelines. Available from: www.adhb.govt.nz/
starshipclinicalguidelines
4. The National Heart Foundation of New Zealand. Guidelines for rheumatic fever. Available from:
www.heartfoundation.org.nz
5. The New Zealand Sexual Health Society (NZSHS). Best practice guidelines. Available from: www.
nzshs.org/guidelines.html

The information in this publication is specifically designed to address conditions and requirements in
New Zealand and no other country. BPAC NZ Limited assumes no responsibility for action or inaction
by any other party based on the information found in this publication and readers are urged to seek
appropriate professional advice before taking any steps in reliance on this information.

29
Respiratory
COPD – acute exacerbations
Pertussis (Whooping cough)
Pneumonia – adult
Pneumonia – child

Ear, nose and throat

Otitis externa – acute
Otitis media
Pharyngitis
Sinusitis – acut

Eyes
Conjunctivitis

CNS
Meningitis and meningococcal septicaemia

Skin
Bites – human and animal Diabetic foot infections
Boils Impetigo
Cellulitis Mastitis

Gastrointestinal
Campylobacter enterocolitis
Clostridium difficile colitis
Giardiasis
Salmonella enterocolitis

Genito-urinary
Bacterial vaginosis Trichomoniasis
Version 1.0  July 2017

Chlamydia Urethritis – acute non-specific

Epididymo-orchitis Urinary tract infection – adult
Gonorrhoea Urinary tract infection – child
Pelvic inflammatory disease Urinary tract infection – pyelonephritis